ASCO Annual Meeting: Genitourinary

For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib.

In AFT-30, increased frequency of PSA screening for localized prostate cancer did not boost survival, regardless of primary treatment or disease risk.

Preliminary findings for pegilodecakin plus immune checkpoint inhibition suggest that the combination is tolerable and shows clinical activity.

In the Abi Race study, response to abiraterone was greater and longer lasting in black men with prostate cancer, compared with white men.

A pooled analysis including data from over 8,000 men showed survival outcomes were better for black men, after adjusting for prognostic variables.

No one molecular biomarker is likely to guide treatment of RCC in the foreseeable future. Multipredictor models might be a way forward, an expert concluded.

Germline genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will test positive for pathogenic gene variants.

Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy.

Pazopanib 600 mg daily as adjuvant therapy did not prolong disease-free survival for patients with locally advanced renal cell carcinoma.

This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients.

Androgen deprivation therapy can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to results of a phase III trial.

Continued enzalutamide with abiraterone failed to improve PFS in men with metastatic castration-resistant prostate cancer who progressed on enzalutamide alone.

Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.

A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.

Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma.

Plasma levels of HGF, BAP1 and PBRM1 gene mutation status, and angiogenesis gene expression are promising predictive biomarkers for survival in RCC patients.

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

In this interview we discuss decision making in the treatment of metastatic renal cell carcinoma.

Abiraterone at the start of ADT for men with metastatic prostate cancer significantly improved overall survival and failure-free survival, with manageable toxicity.

Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer.

In this interview ahead of ASCO 2017 we discuss the physical and cognitive effects of androgen deprivation therapy in older men treated for prostate cancer.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.

Cabozantinib significantly improved the overall survival of patients with previously treated advanced RCC, according to the second interim analysis of the METEOR trial.

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.

Adding carboplatin to cabazitaxel was safe and associated with improved PFS among men with aggressive variant castration-resistant prostate cancer.

A hypofractionated shorter course of radiotherapy was not inferior to a conventional regimen in men with localized prostate cancer.

Cabazitaxel at two different doses was no better than docetaxel with regard to OS or PFS in men with metastatic castration-resistant prostate cancer.